Clinical Trials Logo

Lou Gehrig Disease clinical trials

View clinical trials related to Lou Gehrig Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06315608 Not yet recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

MRG-001 in Patients With Amyotrophic Lateral Sclerosis

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS). MRG-001 will be administered subcutaneously 3 times per week for 2 weeks. This cycle will be repeated for 3 months. In total, patients are expected to receive 18 injections over the span of 3 months.